The first and only FDA-approved methotrexate oral solution
From Silvergate Pharmaceuticals, delivering high-quality medications developed specifically for pediatric patients
Xatmep: The first and only FDA-approved methotrexate oral solution for the treatment of ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) in pediatric patients.
- Assured efficacy delivered with consistent potency.1
- The first and only FDA-approved methotrexate oral solution for ALL.
- Oral solution provides consistent stability when stored as directed.2
- No compounding or crushing tablets necessary.
- No methotrexate injections necessary.
- Body surface area-based dosing.
For information on the treatment of ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), click the appropriate option below, certifying your are either a healthcare provider or a patient or caregiver in the United States.
For information on the treatment of POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (pJIA), click the appropriate option below, certifying your are either a healthcare provider or a patient or caregiver in the United States.
IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION
WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY
See full Prescribing Information for complete boxed warning.
Methotrexate can cause the following severe or fatal adverse reactions.
Monitor closely and modify dose or discontinue methotrexate as appropriate.
- Bone marrow suppression [see Warnings and Precautions (5.1)]
- Serious infections [see Warnings and Precautions (5.2) ]
- Renal toxicity and increased toxicity with renal impairment [see Warnings and Precautions (5.3)]
- Gastrointestinal toxicity [see Warnings and Precautions (5.4)]
- Hepatic toxicity [see Warnings and Precautions (5.5)]
- Pulmonary toxicity [see Warnings and Precautions (5.6)]
- Hypersensitivity and dermatologic reactions [see Warnings and Precautions (5.7)]
- Methotrexate can cause embryo-fetal toxicity, including fetal death. Use in pJIA is contraindicated
in pregnancy. Consider the benefits and risks of XATMEP and risks to the fetus when prescribing
XATMEP to a pregnant patient with a neoplastic disease. Advise females and males of reproductive
potential to use effective contraception during and after treatment with XATMEP [see Contraindications
(4), Warnings and Precautions (5.9), Use in Specific Populations (8.1, 8.3)].
Xatmep is a folate analog metabolic inhibitor indicated for the:
- treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase,
combination chemotherapy maintenance regimen.
ADDITIONAL IMPORTANT SAFETY INFORMATION
Xatmep is contraindicated in pregnant patients with non-malignant disease and in patients with severe
hypersensitivity to methotrexate.
Warnings and Precautions: See full Prescribing Information for additional information.
Adverse Reactions: See full Prescribing Information for additional adverse reactions.
- Xatmep suppresses hematopoiesis and can cause severe and life-threatening pancytopenia, anemia, leukopenia,
neutropenia, and thrombocytopenia. Obtain blood counts at baseline and periodically; monitor patients for
complications of bone marrow suppression.
- Patients treated with Xatmep are at increased risk for developing life-threatening or fatal bacterial, fungal, or viral
infections, including Pneumocystis jiroveci pneumonia, invasive fungal infections, hepatitis B reactivation,
tuberculosis (primary or reactivation), disseminated Herpes zoster and cytomegalovirus infections.
- Renal toxicity and increased toxicity with renal impairment, including acute renal failure. Consider administration
of glucarpidase in patients with toxic plasma methotrexate concentrations (> 1 micromole/liter) and delayed
clearance due to impaired renal function.
- Xatmep can cause diarrhea, stomatitis, vomiting, hemorrhagic enteritis, and fatal intestinal perforation. Patients
with peptic ulcer disease and ulcerative colitis are at increased risk for severe gastrointestinal adverse reactions.
Unexpected severe and fatal gastrointestinal toxicity can occur with concomitant use of NSAIDs.
- Hepatic toxicity: severe and potentially irreversible hepatotoxicity, including fibrosis, cirrhosis, and fatal liver failure
can occur. Avoid use of Xatmep in patients with chronic liver disease.
- Pulmonary toxicity: acute or chronic interstitial pneumonitis and irreversible or fatal cases can occur at all
- Hypersensitivity: anaphylaxis or other serious hypersensitivity reactions. Discontinue methotrexate.
- Severe, including fatal, dermatologic reactions such as toxic epidermal necrolysis, Stevens-Johnson
syndrome, exfoliative dermatitis, skin necrosis, erythema multiforme can occur. Radiation dermatitis and
sunburn may be “recalled.”
- Secondary malignancies can occur at all dose levels. Lymphoproliferative disease has been reported with lowdose
oral methotrexate which regressed when methotrexate is withdrawn.
- Methotrexate can cause embryo-fetal toxicity and fetal death when administered during pregnancy. Consider the
risks and benefits of Xatmep and risks to the fetus when prescribing to a pregnant patient with a neoplastic
disease. Effective contraception should be practiced by patients of reproductive potential while receiving Xatmep
therapy, and for 3 and 6 months afterwards for males and females, respectively. Xatmep is contraindicated in
- Effects on reproduction: Methotrexate can cause impairment of fertility, oligospermia, and menstrual dysfunction.
It is unknown if the infertility is reversible in affected patients.
- Increased toxicity in third-space accumulation. Evacuate significant third-space accumulation prior
to methotrexate administration.
- Immunizations may be ineffective when given during Xatmep therapy.
- Immunization with live virus vaccines is not recommended during Xatmep therapy.
- Concomitant radiation therapy increases the risk of soft tissue necrosis and osteonecrosis associated
- Closely monitor laboratory parameters for hematology, renal function, and liver function. Increase monitoring
during initial dosing, dose changes, and during periods of increased risk of elevated methotrexate blood
levels (e.g., dehydration).
- Pulmonary function tests may be useful if methotrexate-induced lung disease is suspected, especially
if baseline measurements are available.
- Risk of improper dosing: Once-weekly dosing is appropriate. Fatal toxicity has been reported with daily dosing.
An accurate milliliter measuring device should be used. Inform patients that a household teaspoon is not an
accurate measuring device and could lead to overdosage.
- Advise women not to breastfeed during Xatmep therapy.
- Most common adverse reactions are ulcerative stomatitis, leukopenia, nausea, abdominal distress, and elevated
liver function tests.
- Other frequently reported reactions are malaise, fatigue, chills and fever, dizziness, and decreased resistance
Please see full Prescribing Information, including Boxed Warning.
To report SUSPECTED ADVERSE REACTIONS, contact Silvergate Pharmaceuticals at 1-855-379-0383, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
Inform caregivers and patients of the need for proper storage and disposal of dispensing bottles and dosing devices.
Keep this and all medications out of reach of children.
Reference: 1. Xatmep [prescribing information]. Greenwood Village, CO: Silvergate Pharmaceuticals, Inc.; 2017. 2. Data on file, Silvergate Pharmaceuticals, Inc.; 2017.
- Penicillins may reduce the clearance of methotrexate; increased serum concentrations of methotrexate
with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate. Monitor
- Trimethoprim/sulfamethoxazole has been reported to increase bone marrow suppression in patients receiving
methotrexate. Monitor patients accordingly.
- Hepatotoxins: May increase hepatotoxicity. Monitor patients receiving concomitant hepatotoxins for signs
- Probenecid may reduce renal elimination of methotrexate; consider alternative drugs.
- Theophylline: May decrease theophylline clearance. Monitor theophylline levels.